364 Vor Bbiopharma 2022.10.05 Genevieve De Manio Photography Scaled Aspect Ratio 1200 384

Not just a better treatment — a totally novel approach

Vor Bio’s novel approach in the fight against cancer: engineer treatment-resistant Hematopoietic Stem Cells (eHSCs) that allow new, potentially curative targeted therapy opportunities post-transplant.

We aim to protect the healthy cells, expose the cancer.

The Opportunity

We are working to bring the possibility of a cure to patients with high-risk AML, a disease that carries a poor prognosis even with aggressive therapies including traditional Hematopoietic Cell Transplant (HCT), which has been the standard of care for decades.

The Concept

Vor Bio is developing a novel treatment approach—Edit HSCs to enable treatment with powerful targeted therapies post-transplant.

The Science

Vor Bio is developing a proprietary platform built on HSC biology, genome engineering, and CAR-T cells.


Our platform is driving multiple programs in our pipeline. 


We are investing in our own manufacturing facilities and have designed a highly-efficient process for manufacturing our eHSCs and CAR-Ts.


Our vision of a cure for blood cancers is only possible with the collaborative efforts of first-class external partners.